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Patients after implantation of mechanical valves need life-long anticoagulant therapy.
Nearly 30% of these patients have also indication for antiplatelet therapy because of
concomitant ischemic heart disease or peripheral arterial disease. Combined anticoagulant
and dual antiplatelet therapy (so called triple therapy - aspirin, clopidogrel and vitamin K
antagonists) is indicated in patients with acute coronary syndrome and after percutaneous
coronary intervention (PCI) for a different time according to the type of stent used during the
procedure. Triple therapy is substantially more efficacious in reducing the occurrence of
cardiovascular events and mortality in patients undergoing PCI with an indication for long-
term anticoagulant therapy, compared with dual antiplatelet therapy. On the other hand it
carries 3.5 to 4 times higher risk of bleeding in treated patients. Recently new anticoagulants
(dabigatran, rivaroxaban, apixaban) and antiplatelet drugs (prasugrel and ticagrelor) came
into clinical practice and new studies using these drugs are underway.
The purpose of this review article is to summarize current approach to patients with
indication for anticoagulant and antiplatelet therapy after valve surgery.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.Contents1. Indication of antithrombotic therapy and its intensity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
2. Indication of combined anticoagulant and antiplatelet therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
3. Benefits and risks of combined therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
4. New drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
5. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168ch Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
78; fax: þ420 495833026.
kom@seznam.cz (M. Brtko).
.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 1 6 4 – e 1 6 9 e1651. Indication of antithrombotic therapy and its
intensity
According to the European Society of Cardiology (ESC) and
the Czech Society of Cardiology guidelines [1,2] a lifelong
anticoagulant therapy is recommended for all patients with
mechanical heart prostheses (class of recommendation I,
level of evidence B) and for patients with bioprostheses who
have other indications for anticoagulation (atrial fibrillation,
venous thromboembolism, hypercoagulable state, severely
impaired left ventricular function with ejection fraction
o35%)—(class I, level C). Oral anticoagulation should be
considered for the first 3 months after implantation of a
mitral or tricuspid bioprosthesis and for the first 3 months
after mitral or tricuspid valve repair (class IIa, level C).
Warfarin has a narrow therapeutic window and an unpre-
dictable response that requires routine coagulation monitor-
ing and frequent dose adjustment. Despite the disadvantages
of warfarin till now there has been no equivalent alternative
for this drug. The RE-ALIGN study with dabigatran in patients
with mechanical valve prosthesis was stopped because of
increased incidence of valve thrombosis and clinical ischemic
events (see below).
When anticoagulant therapy is prescribed the prosthesis
thrombogenicity, prosthesis position and patient-related
factors should be taken into consideration. Generally Carbome-
dics, Medtronic Hall, St. Jude Medical or ON-X valves belong to
the group of prothesis with low thrombogenicity. Lillehei-
Kaster, Omniscience, Starr-Edwards, Bjork-Shiley and other
tilting-disc valves belong to the group of prosthesis with high
thrombogenicity. Other bileaflet valves not mentioned above
constitute a group with medium trombogenicity. Unfortunately
there are insufficient data on valve thrombosis in newly
introduced valves. The thrombogenicity of the prosthesis in
the aortic position is generally smaller than in the mitral
position; the implantation of the mechanical prosthesis into
the tricuspid or pulmonary position is exceptional.Table 1 – Target international normalized ratio (INR)
recommended for mechanical prostheses [1].
Prosthesis thrombogenicity Patient-related risk factors
No risk factor Risk factor Z1
Low 2.5 3.0
Medium 3.0 3.5
High 3.5 4.0
Patient-related risk factors: mitral or tricuspid valve replacement;
previous thromboembolism; atrial fibrillation; mitral stenosis of
any degree; left ventricular ejection fraction o35%.
Table 2 – The annual risk (%/year) of stroke and systemic emb
valvular atrial fibrillation. Source: Danish national patient regis
LaHaye with permission [34].
Score 0 1 2 3
Reported risk 0.6 1.2 2.6 3.9 6Target international normalized ratio (INR) for prosthesis
with low thrombogenicity in patient with no risk factor is 2.5,
for patient with more than one risk factor 3.0. Target INR for
prosthesis with medium thrombogenicity is 3.0 and 3.5 accord-
ing to presence/absence of risk factors and for prosthesis with
high thrombogenicity 3.5 and 4.0 (Table 1). The following
conditions are considered patient-related risk factors: mitral
or tricuspid valve replacement, previous thromboembolism,
atrial fibrillation, mitral stenosis of any degree and left ven-
tricular ejection fraction o35%.
The most commonly reported anticoagulation regimens
had the following rates of early postoperative (30 days)
thromboembolism and hemorrhage: oral anticoagulation
alone (0.9%, 3.3%); oral anticoagulation with intravenous
unfractionated heparin (1.1%, 7.2%); and oral anticoagulation
with low molecular weight heparin (0.6%, 4.8%)—[3]. After
aortic valve replacement, the risk of thromboembolic events
falls from 16 per 100 patient years in the early postoperative
period to 1.4 per 100 patient years at 5 years. Similarly, after
mitral valve replacement, the risk falls from 21 per 100 patient
years to 2.5 per 100 patient years. The rate of thromboembolic
events after mechanical valve implantation in patients without
anticoagulation therapy is estimated to be 8.6% per year. It
could be approximated, that patients with prosthetic valves
belong to patients with high risk of embolic event according to
CHADS-VASc score, which was developed for patients with
atrial fibrillation (Tables 2 and 3). So the utilization of post-
operative warfarin therapy reduces the incidence of major
embolism by approximately 75%. Neither single nor dual
antiplatelet therapy alone are sufficient in reducing the rate of
valve thrombosis [4–6]. Only one study (135 patients) supporting
the long-term use of dual antiplatelet therapy (aspirin and
clopidogrel) in patients with mechanical aortic valves was
published [7]. The incidence of strokes in this study dropped
from 2.5 %/patient/year to 1.0 %/patient/year after the use of
assays to monitor platelet reactivity. No patient developed
valve thrombosis. Five patients had bleeding complications
(1.2%/patient/year).olism by the CHADS-VASc score in patients with non-
try, 10-year follow-up rates (n¼73,813). Adapted according
4 5 6 7 8 9
.0 9.4 11.6 13.0 13.2 13.9
Table 3 – CHADS-VASc score.
Points
C Congestive heart failure 1
H Hypertension 1
A Age Z75 years 2
D Diabetes mellitus 1
S Stroke/TIA/thromboembolism 2
V Vascular disease 1
A Age 65–74 years 1
S Sex category (female sex) 1
max. 9
Table 5 – HAS-BLED score.
Points
H Hypertension 1
A Abnormal renal and liver function
(1 point each) 1 or 2
S Stroke 1
B Bleeding 1
L Labile INRs 1
E Elderly (e.g., Z65 years) 1
D Drugs or alcohol (1 point each) 1 or 2
max. 9
Hypertension: systolic blood pressure 4 160 mmHg. Abnormal
kidney function: chronic dialysis or renal transplantation or
creatinine Z200 mmol/l. Abnormal liver function: chronic hepatic
disease (e.g., cirrhosis) or biochemical evidence of significant
hepatic derangement (e.g., bilirubin 42x upper limit of normal,
in association with aspartate aminotransferase/alanine amino-
transferase/alkaline phosphatase 43x upper limit normal, etc.).
Bleeding: previous bleeding history and/or predisposition to bleed-
ing, for example, bleeding diathesis, anaemia, and so forth. Labile
INRs: unstable/high INRs or poor time in therapeutic range (e.g.,
o60%). Drugs/alcohol use: concomitant use of drugs, such as
antiplatelet agents, nonsteroidal anti-inflammatory drugs, or
alcohol abuse, and so forth
INR: International normalized ratio.
Table 4 – The annual risk (%/year) of major bleeding by the HAS-BLED score in patients with non-valvular atrial
fibrillation. Source: Danish national patient registry, 1-year incidence (n¼73,813). There were insufficient data to provide a
reliable estimate of the risk of bleeding for patients with HAS-BLED scores greater than seven. Adapted according LaHaye
with permission [34].
Score 0 1 2 3 4 5 6 7
Reported risk 1.2 3.1 5.4 6.5 9.1 12.8 14.1 15.4
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antiplatelet therapy
According to the guidelines [1,2] the addition of low-dose
aspirin should be considered in patients with a mechanical
prosthesis and concomitant atherosclerotic disease (class IIa,
level C) and in patients with a mechanical prosthesis after
thromboembolism despite adequate INR (class IIa, level C).
In patients undergoing percutaneous coronary interven-
tion with stent insertion, dual-antiplatelet therapy reduces
the risk of cardiovascular death or myocardial infarction
compared with aspirin alone or aspirin plus warfarin [8].
Dual-antiplatelet therapy (aspirin plus clopidogrel or prasu-
grel or ticagrelor) is recommended ideally for 1 year in a
patient with acute coronary syndrome, for 1 year after the
implantation of drug-eluting stent and for minimum of 1
month after the implantation of bare-metal stent [9,10]. In a
patient with a mechanical valve triple therapy should be
considered balancing its benefit and risk. With some approx-
imation the risk of bleeding could be estimated according to
HAS-BLED score which was validated for patients with atrial
fibrillation (Tables 4 and 5).
To avoid increased risk of bleeding connected with this
therapy, bare metal stents should be preferred, low level
anticoagulation (INR 2.0–2.5) with frequent INR monitoringand low dose of aspirin (75–100 mg) should be used and
addition of proton-pump inhibitors or H2-antagonists should
be considered. It is necessary to mention that this approach
should apply only for patients with modern prosthesis with
low thrombogenicity and no risk factors (Table 3). Another
possibility to prevent bleeding is to reduce the duration of
triple therapy after drug-eluting stents implantation poten-
tially for 3 months after the implantation of limus eluting
stents or for 6 months after implantation of paclitaxel eluting
stents especially in nondiabetics or low-risk patients [11–14].
It might be possible to continue the treatment with warfarin
and clopidogrel thereafter till 1 year after implantation of
stent with subsequent therapy with warfarin alone. The
support for this approach can be found in the results of
WOEST study, wherein patients on warfarin therapy under-
going PCI, withdrawing of aspirin was superior to the combi-
nation of aspirin and clopidogrel with respect to bleeding
without increasing the thrombotic risk [15].
There is no evidence of improved efficacy of a combined
therapy with an antiplatelet and anticoagulant agent in patient
with periferal arterial disease even though this combination is
frequently used in clinical practice. The rationale for the
combined therapy is that warfarin is superior to antiplatelet
therapy for the prevention of thromboembolic events in
patients with mechanical heart valves whereas antiplatelet
therapy is the standard of care for antithrombotic therapy for
the secondary prevention of serious vascular events in patients
with cardiovascular disease. Because warfarin is also effective
for secondary prevention of serious vascular events, it would
seem reasonable to discontinue aspirin in patients with stable
cardiovascular disease who have a firm indication for warfarin
(e.g. patients with mechanical heart valves)—[16].3. Benefits and risks of combined therapy
A meta-analysis of 2428 subjects compared the efficacy and
safety of adding dipyridamole or aspirin to warfarin with
respect to warfarin alone in patients with prosthetic heart
valves. The combined therapy was shown to reduce throm-
boembolic events (OR 0.39) and total mortality (OR 0.55), with
an increase in major bleeding (OR 1.66). Data were consistent
for both aspirin and dipyridamole [17].
Another meta-analysis of 4 RCTs demonstrated that the
antiplatelet therapy plus anticoagulants were more effective
than anticoagulants alone for the prevention of thromboem-
bolic events in patients with mechanical heart valves [18].
Among 869 patients treated with warfarin dose-adjusted to
achieve an INR of 2–3, aspirin compared with placebo was
associated with a 67% reduction in thromboembolic events
Table 6 – The risk of bleeding in patients with acute
myocardial infarction treated with different combina-
tions of aspirin, clopidogrel and warfarin with aspirin as
a reference [28].
Therapy HR for bleeding
Warfarin 1.23
Clopidogrel 1.33
Aspirinþclopidogrel 1.47
Warfarinþaspirin 1.84
Warfarinþclopidogrel 3.52
Triple therapy 4.05
HR—Adjusted hazard ratio.
Triple therapy—aspirinþclopidogrelþwarfarin.
Table 7 – The risk of bleeding with single, dual or triple
therapy in patients with atrial fibrillation with warfarin
as a reference [29].
Therapy HR for bleeding
Aspirin 0.93
Clopidogrel 1.06
Aspirinþclopidogrel 1.66
Warfarinþaspirin 1.83
Warfarinþclopidogrel 3.08
Triple therapy 3.7
HR—Hazard ratio.
Triple therapy—aspirinþclopidogrelþwarfarin.
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mortality (5.4% vs. 7.9%, RR 0.43) at the cost of a 58% increase
in bleeding (13.1% vs. 8.1%, RR 1.58). The dose of aspirin in
these trials varied from 100 mg daily to 500 mg BID
and follow-up in the studies ranged from 1 to 2.5 years.
The benefits of adding aspirin to warfarin were primarily
driven by the study by Turpie et al., which included 370
patients and demonstrated a 77% reduction of systemic
embolism or cardiovascular death compared to warfarin
alone. Most of the benefits occurred in patients with con-
comitant coronary artery disease [19].
Meschengieser and colleagues randomized 503 patients
with mechanical valves who received aspirin 100 mg once
daily plus warfarin (target INR 2.5–3.5) or warfarin alone
(target INR 3.5–4.5) for a median of 2 years in an open-label
fashion. The group randomized to aspirin and warfarin
therapy had similar rates of thromboembolic and bleeding
events as those that received warfarin alone but the combi-
nation significantly reduced all-cause mortality (3.5% vs.
8.6%, RR 0.41)—[20].
The meta-analysis data provide clear evidence of a reduc-
tion in thromboembolic events and death when aspirin is
added to warfarin in patients with mechanical heart valves.
However, this summary is based on small trials, and most of
these were conducted several decades ago. Furthermore, it
appears that the benefits of aspirin were largely seen in
patients with coronary artery disease. It is uncertain whether
similar efficacy benefits of aspirin would be evident in trials
conducted in the modern era with newer valves and better
anticoagulant management and in patients without conco-
mitant coronary artery disease [21].
If combined therapy is prescribed it should be taken into
account that the mortality rate of a potential intracerebral
hemorrhage is reported to be 67% in patients on oral antic-
oagulant treatment [22].
In meta-analysis of Paikin 2.2% rate of major bleeding at
30 days and 12% at 1 year is reported [23]. Most patients in
this meta-analysis were receiving warfarin for atrial fibrilla-
tion and dual-antiplatelet therapy for a coronary artery stent.
This is in agreement with the results of other studies [24–26].
The risk of bleeding increases up to four to fivefold at 6
months and five to eightfold at 12 months as combined
antithrombotic therapy is prolonged.
From the study of Lamberts et al. [27] emerges, that both
early (within 90 days) and delayed (90–360 days) bleeding risk
with triple therapy exposure in relation to warfarinþantiplate-
let was increased (hazard ratio 1.47 and 1.36, respectively).
No significant difference in thromboembolic risk was observed
for triple therapy versus warfarinþantiplatelet (hazard ratio
1.15). The authors conclude, that high risk of bleeding is
immediately evident with triple therapy after myocardial
infarction/PCI in patients with atrial fibrillation. A continually
elevated risk associated with triple therapy indicates no safe
therapeutic window.
Detailed data concerning the risk of bleeding in patients
with a different combination of aspirin, clopidogrel and
vitamin K antagonist are accessible from the Danish registry
[28,29]. Sorensen studied the risk of bleeding in patients who
had been admitted to hospital with acute myocardial infarc-
tion (Table 6). 37.9% of 1852 patients with non-fatal bleedinghad recurrent myocardial infarction or died during the study
period compared with 18.4% of 38,960 patients without non-
fatal bleeding (HR 3.00, po0.0001). The authors conclude, that
the risk of bleeding is proportional to the number of drugs
used and that non-fatal bleeding is an independent predictor
associated with the increased risk of recurrent myocardial
infarction or death. Conclusions of Hansen’s study are simi-
lar: in patients with atrial fibrillation, all combinations of
warfarin, aspirin, and clopidogrel are associated with
increased risk of nonfatal and fatal bleeding; dual warfarin
and clopidogrel therapy and triple therapy carried a more
than 3-fold higher risk than did the warfarin monotherapy
(Table 7).4. New drugs
The results of 2 studies (APPRAISE-1 and ATLAS TIMI-46)
comparing the new oral factor Xa inhibitors, apixaban and
rivaroxaban, to antiplatelet therapy alone for the long-term
management of ACS patients are promising. However, both of
the new anticoagulants increased bleeding in a dose-dependent
manner and were associated with a smaller reduction of
ischemic events and a greater increase in bleeding when added
to dual antiplatelet therapy compared with when they were
added to aspirin alone [30,31]. The third generation of P2Y12
antagonists (ticagrelor, prasugrel) increase also the incidence of
major bleeding compared to clopidogrel, conceivably limiting
their use in triple therapy [32,33]. These drugs have not yet been
tested systematically in patients with mechanical heart valves.
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tested in patients with atrial fibrillation in the ENGAGE AF
TIMI 48 study (ClinicalTrials.gov Identifier NCT00781391) as
well as in a Chinese study (ClinicalTrials.gov Identifier
NCT00806624). Till now we have no data for using this drug
in patients with mechanical heart valves.
The efficacy of dabigatran in patients after the implanta-
tion of mechanical heart valves (population A—recent sur-
gery group, population B—remote surgery group) was
examined in RE-ALIGN study (ClinicalTrials.gov Identifier
NCT01505881). Due to a lower than projected exposure
together with an excess of clinical ischemic events and valve
thrombosis in both groups in patients receiving dabigatran,
the study has been recently terminated.5. Conclusions
The anticoagulation therapy using vitamin K antagonists is
still the cornestone therapy in patients with mechanical
heart valves. Currently there is no equivalent alternative to
warfarin in this indication. Warfarin substantially decreases
the risk of thromboembolism with an acceptable risk of
bleeding when optimally managed. The combination of
warfarin and aspirin reduces thromboembolic events and
total mortality even more at the cost of an increased rate of
bleeding. The triple therapy yields the highest rate of bleed-
ing. Every effort should be made to shorten the duration of
triple therapy as much as possible (potentially to 3–6 months
according to the type of implanted stent) or to modify the
number of antithrombotic drugs concomitantly used. Pre-
sently there are no sufficient data to recommend new
antithrombotic drugs separately or in combination for
patients with mechanical heart valves and with indication
to combined antithrombotic therapy.
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